纽约

我们是谁

  • 8 月 31, 2023
    A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors
  • 7 月 24, 2023
    Fc-Engineered Anti-CTLA-4 Monoclonal Antibody Botensilimab in Advanced Cancer
  • 2 月 7, 2023
    A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer Without Liver Metastases
  • 12 月 8, 2022
    Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation
  • 12 月 1, 2022
    Phase 2 Study of DKN-01 in Colorectal Cancer
  • 11 月 15, 2022
    Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer (STELLAR-303)
  • 5 月 23, 2022
    索托拉西布和帕尼单抗与研究者选择治疗克氏鼠肉瘤（KRAS）p.G12C 突变患者（代码 300）
  • 4 月 5, 2022
    CPI-0209 对晚期实体瘤和淋巴瘤患者的研究
  • 4 月 5, 2022
    Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Participants With Resected Solid Tumors and in Combination With Pembrolizumab in Participants With Unresectable Solid Tumors
  • 4 月 5, 2022
    测试不同剂量的 BI 1823911 单独或与其他药物联合用于不同类型的 KRAS 基因突变晚期癌症患者的研究